Evaluation of an artificial intelligence-based medical device for diagnosis of autism spectrum disorder.

Autism spectrum disorder (ASD) can be reliably diagnosed at 18 months, yet significant diagnostic delays persist in the United States. This double-blinded, multi-site, prospective, active comparator cohort study tested the accuracy of an artificial intelligence-based Software as a Medical Device designed to aid primary care healthcare providers (HCPs) in diagnosing ASD. The Device combines behavioral features from three distinct inputs (a caregiver questionnaire, analysis of two short home videos, and an HCP questionnaire) in a gradient boosted decision tree machine learning algorithm to produce either an ASD positive, ASD negative, or indeterminate output.

Safety and Efficacy of Cannabis in Autism Spectrum Disorder.

Investigators from the Soroka University Medical Centre, The Hebrew University of Jerusalem, and Tikun Olam Ltd. in Israel studied the safety and efficacy of medical cannabis treatment on 188 patients with autism spectrum disorder (ASD) for six months.

Children with Psychogenic Nonepileptic Seizures.

A large multicenter retrospective cohort study was conducted by researchers from the Pediatric Health Information System hospital network to determine differences in demographics, clinical characteristics, testing, treatment, and healthcare use between children aged 8-20 years with epilepsy ( = 13,241) and those with psychogenic nonepileptic seizures (PNES) secondary to conversion disorder ( = 399).

Persistent Postconcussive Symptoms in Children and Adolescents.

Investigators from the Children's Hospital of Eastern Ontario, Boston Children's Hospital, Alberta Children's Hospital, University of Montreal, McGill University Health Center, Hospital for Sick Children, University of Calgary, and the University of Ottawa researched the association between early physical activity and persistent postconcussive symptoms (PPCS).

Pharmacokinetics and Optimal Dosing of Phenobarbital.

Researchers from the Baylor College of Medicine in Houston, TX, USA, conducted a analysis of 355 patients ages less than 19 years of age in the inpatient setting who were initiated on intravenous or oral phenobarbital therapy and had one or more serum phenobarbital concentrations sampled.